$XBI $123.70 +1.57%
Covid Updates
$GRTS +8.5% Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern. source
$TLSA +3.6% Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil. source
Pipeline Updates
$ANAB +6.6% FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors. source
$MRNS -0.7% Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation. source
$AGIO +2.4% Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency. source
$JAGX -1.7% Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea. source
$APVO -4.5% Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome. source
$MEIP -1.5% MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma. source
$AUPH -9.8% Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases. source
$ACRX -16.6% On 8/16 AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results. source
$OSMT -15.0% On 8/16 Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update. source
$TERN +17.2% On 8/16 Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights. source
$PRAX +18.3% On 8/16 Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results. source
$SESN +23.8% On 8/13 Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs). source
Posted by FS
Comments